| Expression pattern: |
UP |
| Associated gene: |
CDCA7, RRM2 |
| Associated microRNA: |
miR-515-5p |
| Biological function: |
inhibits ferroptosis and promotes cisplatin resistance, supporting cell viability and invasion while inhibiting apoptosis |
| Molecular mechanism: |
circASH1L acts as a ceRNA sponge of miR-515-5p to regulate CDCA7, which interacts with RRM2 to inhibit RRM2 degradation, thereby modulating cell cycle arrest and ferroptosis resistance |
| Biological pathway or process: |
ferroptosis (inhibits); chemoresistance (promotes); cell cycle (promotes); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; FISH / smFISH; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Co-IP; Transfection; CCK8; Transwell Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; Bioinformatics Analysis; Survival Analysis; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
High circASH1L expression was higher in cisplatin-resistant group and was significantly associated with shorter overall survival |
| Description: |
In cisplatin-resistant ovarian cancer cells, circASH1L is upregulated and promotes chemoresistance by inhibiting ferroptosis. It sponges miR-515-5p to upregulate CDCA7, which supports RRM2 stability and cell-cycle progression, thereby reducing ferroptotic responses and sustaining drug resistance. |
| Confidence score: |
0.8748 |